摘要
目的规察单唾液酸四己糖神经节苷脂（GMl）治疗血管性认知障碍（vascularcogaitive impairment，VCI）的疗效。方法60例VCI患者随机分为治疗组和对照组，其中对照组接受常规治疗，治疗组在常规治疗基础上加用GM1（80mg／d）连续静脉滴注2周。在治疗前和治疗后采用蒙特利尔认知评估量表（Montreal Cognitive Assessment，MoCA）评定疗效，并观察治疗安全性。结果治疗2周后两组MoCA评分均显著高于治疗前（P均〈n05），治疗组MoCA评分显著高于对照组（20．824±1．96对19．61±202，t：2．315，P=0．023），未发现明显不良反应。结论单唾液酸四己糖神经节苷脂治疗VCI的疗效肯定，且无严重不良反应，值得临床推广使用。
Objective To observe the efficacy of monosialotetrahexosyl^ngtioside （GM1） in the treatment of vascular cognitive impairment （VCI）. Methods Sixty patients with VCI were randomly divided into either a treatment group or a control group. The patients in the control group received conventional treatment and those in the treatment control group were treated with conventional treatment plus continuous intravenous infusion of GM1 （80 mg/d） for 2 weeks. The efficacy was evaluated by the Montreal Cognitive Assessment （MoCA） before and after the treatment, and the safety of the treatment was observed. Results After 2 weeks of treatment, the MoCA scores were significantly higher than those before treatment in both groups （all P 〈0. 05）. The MoCA scores of the treatment group were si^aificantly higher than those of the control goup （20. 82 ± 1.96 vs. 19. 61 ±2. 02, t=2. 315, P =0. 023）. No obvious adverse reactions were found. Conclusions The efficacy of GM1 is positive in the treatment of vascular cognitive impairment, and there is no obvious adverse reactions. It is worthy of using widely in clinical practice.
出处
《国际脑血管病杂志》
北大核心
2011年第5期386-388,共3页
International Journal of Cerebrovascular Diseases
基金
广东省科技计划项目基金（200913030801108）
广东省自然科学基金（8151008901000027）
关键词
认知障碍
脑血管障碍
神经节苷脂类
Cogaition disorders
Cerebrovascular disorders
Gangliosides
